Home
overview

Special Managers Rate £799, limited availability. Book online today

Following on from our hugely successful Cell-Based Assays conference in 2012 SMi will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.
 

Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.

There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.

Toxicology is generally difficult to predict, even in animal models. This has paved the way for high content screening assays using stem cell derived cardiomyocytes and hepatocytes can facilitate the determination as complex responses from specific drugs. See at cell based assays 2013 how HCA can be utilised in your pre-clinical toxicology procedures to give highly accurate tox data.

Over 13 big pharma speakers will demonstrate to you everything we need to know in CBA development including innovative case studies, including a unique 4 stage 'Big Pharma Spotlight' on Ion Channel targeting development.


 

Cell based assays 2013 will aims to show you the latest developments from this hugely exciting and growing field. With case studies on new drugs being produced for ion channel targeting and phenotypic screening approaches to drug discovery. New topics including human derived primary cellular assays and stem cell technologies that are currently being used in a variety of preclinical toxicology settings. We will also have updates from the best in 3 dimensional cell culture - see how this exciting field is revolutionising how preclinical toxicology studies are currently being run.

  • Through unique ‘Big Pharma Spot Light Sessions’ Cell Based Assays 2013 can show you the latest developments coming from pharma laboratories all over the world including:

              i. Assay development of multi-subunit ion channel channels for drug screening – Special 4 stage big pharma case study spot light

               ii. How SAR-driving assays are improving the physiological relevance of primary cells

               iii. MedImmune case study of biomarker assay platforms in anti-viral vaccines

               iv.2D vs 3D cell responses to panels of chemotherapeutic agents

  • Cell based assays now in its sixth year provides an unparalleled view into the current trends of this highly dynamic, complicated area.
  • Over 95 delegates last year with interactive exhibition area adjacent
  • 12 industry led speaking topics
  • Extremely popular workshop series focussing on 3D cell culture and its future applications in drug discovery
  • Learn from industry and model studies for effective uptake of these areas into your business model
  • Screening
  • Pre-clinical Research
  • Pharmacology
  • Lead discovery technologies
  • Molecular and cellular biology
  • Biological technologies
  • Lead generation and optimization
  • High-content analysis
  • Target identification and validation
  • Target discovery
  • In vitro assays
  • Compound profiling
  • Assay development
  •  

3D Biomatrix, Inc.; Actelion Ltd. ; Actelion Pharmaceuticals; Adams Business Associates; Apitope Technology (Bristol) Ltd; Bayer; BBTC; BD Biosciences; Boehringer Ingelheim; Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim Pharma Informacios Es Szerviz Iroda; Cancer Research Technology; Cancer Research UK; Caroucell; CellAura; Charite Berlin; Corning Life Sciences; CRT; deMello Research Group; Entrepreneur's Fund; Finn-Medi Research Ltd; Galapagos Genomics; Genetic Engineering News; GlaxoSmithKline; Greiner Bio-One; Hamilton UK; Hypha Discovery Ltd; Imagen Biotech; Imperial College; Imperial College London; Institute of Cancer Research; Kings College London; Kings College University; Kuraray Co Ltd; Kymab Ltd; Labcyte Inc; MaxCyte, Inc.; Merck & Company Incorporated Usa; Merz Pharma GmbH & Co. KGaA; MRC Technology; Novartis; Novartis Horsham Research Centre; Novartis Pharmaceuticals; Novo Nordisk; Orion Pharma Animan Health; Oxford University; PerkinElmer; Philip Morris ; Philip Morris Products SA; Recordati Industria Chimica E Farmaceutica S P A; Reinnervate; ReInnervate Limited; Sanofi Aventis; SymCel Sverige AB; Syngenta; Takeda Cambridge; TAP Biosystems; Tecan Austria GmbH; The Electrospinning Company; Trinity College Dublin; UCB-Celltech; UCL Medical School Royal Free Campus; University College London;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Anthony Davies

Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

9:10 Expanding the use of primary cell systems in hit identification and compound profiling

Steve Ludbrook

Steve Ludbrook, Section Head, GlaxoSmithKline

  • Current focus on translationally-aligned drug discovery approaches
  • Potential to accelerate the uptake of primary cell screening systems
  • Primary cell systems utilised as GSK
  • Increased usage of phenotypic assays and primary screening activities for hit identification
  • 9:50 Phenotypic screening based on automated imaging to identify EMT inhibitors

    Urs Luethi

    Urs Luethi, Senior Lab Head Lead Discovery, Actelion

  • Phenotypic rather than target-based screening
  • Generating multiparametric readout based on automated imaging
  • Identification of small molecules that block the EMT (epithelial-to-mesenchyme transition)
  • Case study
  • 10:30 Morning Coffee

    11:00 Improving the physiological relevance of SAR-driving assays with primary and stem cells

    Martha Brown

    Martha Brown, Senior Associate Director, Compound Profiling, Boehringer Ingelheim

  • Immortalized cell lines in drug discovery
  • Overview of primary and stem cells in the context of SAR-driving assays
  • Case studies
  • 11:40 Development of high-throughput recombinant assays for ENaC drug discovery

    Mark Mao Xiang Chen

    Mark Mao Xiang Chen, Biological and Cellular Targets, , GlaxoSmithKline

  • ENaC is an important drug target 
  • Robust functional expression of  3 subunits overcoming cellular toxicity
  • Planar array electrophysiology and FLIPR assays
  • HTS and compound profiling
  • 12:20 Networking Lunch

    13:50 Multi-platform analysis approaches for the evaluation of in 3D biological systems in vitro

    Anthony Davies

    Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

  • Practical issues surrounding 3D cell based assays in research
  • Experimental approaches we have under taken to implement a multiplatform analysis of in vitro assays
  • Demonstrate the feasibility of performing assays in an automated screening environment
  • 14:30 Translating drug combinations from in vitro to clinic – 2D or 3D cultures ?

    Eric Tang

    Eric Tang, Associate Principle Scientist, AstraZeneca

  • Introductions to 3D culture methods
  • Successful translations from traditional 2D methods
  • AstraZeneca case study
  • 15:10 Afternoon Tea

    15:40 Cell-based Biomarker Assay Platforms in Support of the Clinical Development of Anti-viral Vaccines and mAbs at MedImmune

    Fengrong Zuo

    Fengrong Zuo, Principal Scientist, Group Leader Bioassays/Serology, MedImmune

  • Overview of the Cell-based Assay Platforms used for Vaccine Drug Development at MedImmune
  • Development of the Fluorescence-based RSV infectivity and its microneutralization vs MSD-based IgG assays
  • Their utility in phase I clinical study as the immunogenicity biomarkers for the Live Attenuated RSV Vaccine MEDI559
  • Performing assays in an automated screening environment
  • 16:20 Using High Content screening to compare 2D Vs 3D cell responses to a panel of chemotherapeutic agents

    Gareth  Griffiths

    Gareth Griffiths , Chief Scientific Officer, Imagen Biotech

  • Current Techniques in 3D culture
  • Using 3 Assays  (the 3D hanging drop technique, 2D, and stem cell side population) to compare different breast cancer line response to drugs
  • Description of techniques to isolate glioblastoma stem cells from patients
  • Subsequent screening of these lines in 2D Vs 3D and generation of compound ‘fingerprints’ for each line
  • 17:00 Studies of yeast metabolism in the unique culture environment of microgravity

    Timothy Grant  Hammond

    Timothy Grant Hammond , Senior Medical Officer , US Department of Veterans Affairs/ Duke University

    •         Unique opportunities afforded by space flight
    •         Low shear suspension culture
    •         Reduced gravity dependent convection for volatile gas signalling
    •         The unique pathway analysis determined in space

    17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Anthony Davies

    Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

    9:10 Assay development of multi-subunit ion channels for drug discovery screening using MaxCyte electroporation: GABA-a receptors

    Tyrell Norris

    Tyrell Norris, Team Leader - Celluar Reagents and Assay Development, AstraZeneca

    Assay development for multi-subunit ion channels
    Scalable transient expression using electroporation
    Comparison of multiple assay platforms
     

    9:50 Luciferase based Complementation assay to dissect GPCR signaling pathways

    Xavier Leroy

    Xavier Leroy, Associate Director, Project Leader, Actelion

  • GPCR pathways activation
  • GRKs, Beta-arrestin 2
  • Endosome, Lysozome, internalization
  • Biased agonists
  • 10:30 Morning Coffee

    11:00 Strategies for screening ion channel drug discovery targets

    Pamela Tranter

    Pamela Tranter, Investigator III, Novartis

  • New technologies and  applications of automated electrophysiology platforms 
  • Approaches for developing Ion channel cell based assays
  • The challenges with  profiling transient receptor potential (TRP) ion channels
  • 11:40 Exploring capabilities of IonWorks Barracuda for ion channel safety profiling in early stage drug discovery

    David Standing

    David Standing, Senior Scientist, GlaxoSmithKline

  • Increasing throughput and lowering cost
  • Detecting slow-acting compounds
  • Extending high throughput electrophysiology to Cys-loop transmitter-gated ion channels
  • Optimising assay performance
  • 12:20 Networking Lunch

    13:50 A new adaptation to the BacMam system

    Michiel van Diepen

    Michiel van Diepen, Scientist II, Novartis

  • Introductions to the BacMam system
  • Recent applications of the study
  • Case study
  • 14:30 FLIM HCA from Automated Multiwell Plate Assays to Live Disease Models

    Paul French

    Paul French, Head of Photonics Group, Imperial College London

  • Flourescence lifetime imaging (FLIM)
  • Reading protein interactions in automated multiwell plate readers in live disease models
  • Application of FLIM plate reader to exemplar assay of HIV-Gay protein aggregation with dose response resulting in Z'>0.5
  • 15:10 Afternoon Tea

    15:40 Use of human pluripotent stem cell derivatives as cardiovascular disease models

    Sian Harding

    Sian Harding, Head of Myocardial Function Section, Imperial College London

  • Human embryonic and induced pluripotent stem cells
  • Advantages of high content screening
  • Unique characteristics of cardiomyocyte cultures
  • Development of cardiotoxicity and cell growth assays
  • 16:20 Supplying Donated Human Tissue for Cell Based Assays

    Amir Gander

    Amir Gander, Senior Knowledge Transfer Associate, UCL Medical School

  • Infrastructure needed to delivery human tissue samples
  • How tissue is used at UCL
  • Industrial collaborators
  • Challenges and solutions to high quality tissue provision
  • 17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Anthony Davies

    Anthony Davies

    Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
    Fengrong Zuo

    Fengrong Zuo

    Principal Scientist, Group Leader Bioassays/Serology, MedImmune
    Mark Mao Xiang Chen

    Mark Mao Xiang Chen

    Biological and Cellular Targets, , GlaxoSmithKline
    Martha Brown

    Martha Brown

    Senior Associate Director, Compound Profiling, Boehringer Ingelheim
    Michiel van Diepen

    Michiel van Diepen

    Scientist II, Novartis
    Steve Ludbrook

    Steve Ludbrook

    Section Head, GlaxoSmithKline
    Tyrell Norris

    Tyrell Norris

    Team Leader - Celluar Reagents and Assay Development, AstraZeneca
    Urs Luethi

    Urs Luethi

    Senior Lab Head Lead Discovery, Actelion

    Amir Gander

    Senior Knowledge Transfer Associate, UCL Medical School
    Amir Gander

    Anthony Davies

    Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
    Anthony Davies

    David Standing

    Senior Scientist, GlaxoSmithKline
    David Standing

    Eric Tang

    Associate Principle Scientist, AstraZeneca
    Eric Tang

    Fengrong Zuo

    Principal Scientist, Group Leader Bioassays/Serology, MedImmune
    Fengrong Zuo

    Gareth Griffiths

    Chief Scientific Officer, Imagen Biotech
    Gareth  Griffiths

    Mark Mao Xiang Chen

    Biological and Cellular Targets, , GlaxoSmithKline
    Mark Mao Xiang Chen

    Martha Brown

    Senior Associate Director, Compound Profiling, Boehringer Ingelheim
    Martha Brown

    Michiel van Diepen

    Scientist II, Novartis
    Michiel van Diepen

    Pamela Tranter

    Investigator III, Novartis
    Pamela Tranter

    Paul French

    Head of Photonics Group, Imperial College London
    Paul French

    Sian Harding

    Head of Myocardial Function Section, Imperial College London
    Sian Harding

    Steve Ludbrook

    Section Head, GlaxoSmithKline
    Steve Ludbrook

    Timothy Grant Hammond

    Senior Medical Officer , US Department of Veterans Affairs/ Duke University
    Timothy Grant  Hammond

    Tyrell Norris

    Team Leader - Celluar Reagents and Assay Development, AstraZeneca
    Tyrell Norris

    Urs Luethi

    Senior Lab Head Lead Discovery, Actelion
    Urs Luethi

    Xavier Leroy

    Associate Director, Project Leader, Actelion
    Xavier Leroy

    Workshops

    Cell-Based Assays – Sponsor Manual

    Download

    Cell-Based Assays – Delegate Prospectus

    Download

    Closer to Real 3D Cell Culture Advances

    Download

    Novel 3D Cell Culture Systems

    Download

    Short Q&A with an Expert: Dr. Timothy Hammond

    Download

    A novel, rapid and reproducible method for creating 3-D cell cultures to study complex cell behaviour.

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.